The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors

The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors

IntroductionHormonal therapy (HT) blocks the hormone-mediated growth signal dramatically reducing estrogenic levels with aromatase inhibitors (AIs) becoming a crucial component of the treatment mainstay in patients with early breast cancer (BC). Postmenopausal BC patients receiving HT present with a...

Full description

Bibliographic Details
Main Authors: Antonio Galvano, Valerio Gristina, Dalila Scaturro, Tancredi Didier Bazan Russo, Sofia Tomasello, Fabio Vitagliani, Federica Carità, Maria La Mantia, Fabio Fulfaro, Viviana Bazan, Giulia Letizia Mauro, Antonio Russo
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Endocrinology
Subjects:
alendronate
denosumab
secondary osteoporosis
pain control
breast cancer
aromatase inhibitors (AIS)
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1297950/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1297950/full

Similar Items